-
Share
684 Posts.
119
11/09/20
16:38
Share
Listening the the interview, GHVD looks to be a given, it is the only way you could interpret SI's comment.
Picked this up off another site- https://www.fiercepharma.com/pharma/mesoblast-scores-fda-committee-s-backing-for-cell-therapy-despite-some-early-worries
In February 2018, Mesoblast posted pivotal phase 3 data in pediatric GVHD showing 69% of Ryoncil patients had a complete or partial response to the treatment after 28 days. The therapy is already approved as Temcell in Japan, where it is licensed to JCR Pharma.
(20min delay)
